Biomarker-driven therapies for metastatic uveal melanoma: A prospective precision oncology feasibility study

Serge Leyvraz,Frank Konietschke,Caroline Peuker,Moritz Schütte,Thomas Kessler,Sebastian Ochsenreither, Marc Ditzhaus,Erin D Sprünken,Gina Dörpholz,Mario Lamping,Damian T Rieke,Konrad Klinghammer,Susen Burock,Claas Ulrich,Gabriela Poch,Reinhold Schäfer,Frederick Klauschen,Antonia Joussen,Marie-Laure Yaspo,Ulrich Keilholz

European Journal of Cancer（2022）

引用 2|浏览24

暂无评分

摘要

•Demonstration of the feasibility of precision oncology for advanced uveal melanoma.•Complete whole-genome and RNA sequencing data were generated for 87% of patients.•Following treatment recommendations, 60% of patients received ≥1 matched therapy.•First-line therapies included inhibitors of MEK, MET, sorafenib, and nivolumab.•Clinical benefit rate in 56% of patients with one partial response under nivolumab.

查看译文

关键词

Uveal melanoma,Precision oncology,Targeted therapy,High-throughput genomics

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要